



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 03 Aug 2020 (#35)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Upcoming Deadlines

- [Global Infectious Disease Research Training](#) D71 28 October 2020
- [HIV Research Training Program for LMIC Institutions](#) 20 August 2020
- [Mobile Health: Technology and Outcomes in LMICs](#) 24 September 2020; AIDS deadline 3 December 2020
- [Fulbright-Fogarty Fellows in Public Health](#) 13 October 2020
- [Emerging Global Leader Award](#) 4 November 2020
- [Global Brain Disorders Research](#) 6 November 2020
- [Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs](#) 12 November 2020
- [Chronic, Noncommunicable Diseases and Disorders Research Training \(NCD-Lifespan\)](#) D43 13 November 2020
- [Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#) 18 November 2020

Important Notices

- [NOT-OD-20-154](#) Findings of Research Misconduct
- [NOT-RM-20-024](#) Notice of Technical Assistance Webinars for Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) RFAs: RFA-RM-20-015, RFA-RM-20-016, RFA-RM-20-017, RFA-RM-20-018
- [NOT-AG-20-046](#) Notice to extend the expiration date of [PAR-18-190](#) and [PAR-18-189](#) *Multidisciplinary Studies of HIV/AIDS and Aging (Clinical Trial Optional)*. Expiration Date is now 8 January 2021.
- [NOT-DA-20-069](#) Notice of Intent to Publish a Funding Opportunity Announcement for **HEALTHY Brain and Child Development Study**. The primary objective of the HBCD Project is to conduct a large scale multi-site longitudinal study that can prospectively examine human brain, cognitive, behavioural, social, and emotional development beginning at birth and extending through middle childhood.
- [NOT-CA-20-092](#) Notice of Information: **FNIH Cancer Steering Committee Project Concepts for Novel Biomarker Platforms in Understanding Tumor Heterogeneity**. The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) is issuing a Request for Proposals (RFP) for novel biomarker platforms to support the mission of the BC Cancer Steering Committee (CSC) High Content Data Integration Working Group (HCDI WG). The HCDI WG invites investigators to submit brief project concept proposals for application of novel biomarker platforms to either of two clinical challenges. These proposals will be considered for funding under the BC precompetitive project model. Receipt Date for this RFP is August 31, 2020, 11:59 PM ET. See: <https://fnih.org/csc-hcdi-rfp>

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunities

1. Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-254](#)

Type: R01

Application Due Date: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years, but given how quickly the field is evolving, it is expected that many projects will be no more than 3 years in duration. Longer project periods should be well justified.

2. Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-255](#)

Type: R21

Application Due Date: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Budget: Application budgets are limited to a combined total of no more than \$275,000 in direct costs for the two year project, with no more than \$200,000 in direct costs in a single year. Budgets should include costs required to develop and implement the proposed Resource Sharing Plan. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

3. Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-257](#)

Type: R03

Application Due Date: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

Budget: Application budgets are limited to no more than \$50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

4. Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-279](#)

Type: UG3/UH3

Application Due Date: December 15, 2020; August 10, 2021; December 14, 2021; August 10, 2022; December 14, 2022; August 10, 2023: Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new devices or existing devices approved for other indications. Applications may evaluate the mechanism of action of a device. The UG3/UH3 Cooperative Agreement involves 2 phases. The UG3 phase, for up to 2 years, is designed to support a project with specific milestones to be accomplished by the end of the period. The UH3 phase is to provide funding for up to 3 additional years following successful completion of the UG3. UG3 projects that meet their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators submitting to this FOA must address both UG3 and UH3 phases.

Budget: Application budgets are limited to \$500,000 direct costs for each year of the UG3 phase but are not limited for the UH3 phase. However, budgets need to reflect the actual needs of the proposed project. The project period is limited to 2 years for the UG3 phase and 3 years for the UH3 phase.

5. Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-21-029](#)

Type: R01

Application Due Date: November 10, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain comprehensive mechanistic understanding of the impact of sex differences on the trajectories of brain aging, phenotypes, and risk of Alzheimer's Disease (AD) and AD-related dementia (ADRD), and on precision medicine for treatment and prevention of AD/ADRD, including the responsiveness to pharmacologic and non-pharmacologic interventions.

Budget: NIA intends to commit \$5.5 million in FY 2021 to support 2-5 awards. Annual direct costs are capped at \$750,000. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

6. Investigator-Initiated Research on Genetic Counselling Processes and Practices (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HG-20-048](#)

Type: R01

[RFA-HG-20-049](#)

R21

Application Due Date: Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this initiative is to support investigator-initiated research on genetic counselling processes and practices in genomic medicine. Research is needed to optimize the genetic counselling process in the context of limited resources. Applications will assess, innovate, scale, and/or research the implementation of novel genetic counselling practices to address the need for more healthcare professionals trained in genetic counselling; the uneven access to in-person genetic counselling across U.S. health care systems; and the challenges of effective and efficient communication of genomic findings to clinicians, patients, and families.

Budget: The following NIH components intend to commit the following amounts in FY 2021: NHGRI, up to \$4M total costs, 3-5 awards. NCI, up to \$800K total costs, 1 award. R01 = Application budgets are limited to \$500,000 direct costs/year. Application budgets need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years. R21 = NHGRI intends to commit up to \$1.5M total costs to fund 3-5 awards. Application budgets are limited to \$400,000 direct costs for up to three years with no more than \$200,000 direct costs/year. Application budgets need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105